ESMO IOTECH
@esmo_iotech
Followers
351
Following
146
Media
37
Statuses
137
IOTECH publishes pre-clinical & clinical studies covering natural & therapy-induced innate & adaptive immune responses against solid/haematological cancers
Joined September 2021
IOTECH is the newest @myESMO #OpenAccess journal. We aim to publish the highest quality #immunooncology research and aspire to provide a forum for leaders in the IO field. Led by EIC @HaanenJohn, we look forward to receiving your research manuscripts. https://t.co/xHaxHvN38J
0
8
23
The impact of #GutMicrobiota on #immunotherapy response and resistance has been established, but studies presented at #ESMOImmuno24 highlight important associations between microbiota and immunotherapy-related toxicities.โฏ #ESMODailyReporter ๐ https://t.co/ipZmd9Sh3w
1
4
6
#ESMOImmuno24: According to the 2024 ESMO Immuno-Oncology Awardee, @Schumacher_lab, tackling the T-cell receptor challenge w/ vast datasets and cutting-edge high-throughput methods may pave the way for advances in #immunotherapy. #ESMODailyReporter ๐ https://t.co/FyknBm6pAB
0
3
12
It's finally here! #ESMOImmuno24 ๐ Delighted that all accepted abstracts, including late-breaking abstracts, will be published online in the 'ESMO Immuno-Oncology Congress 2024 Abstract Book', a supplement to @esmo_iotech.
๐ฃ #ESMOImmuno24: J. Haanen, J. Naidoo, K. Harrington and A. di Giacomo highlight the benefits of sharing your research at this event. โฐ Deadline: 1 October ๐
Dates: 11-13 December 2024 ๐ Location: Geneva, Switzerland ๐ Submit your abstract: https://t.co/9tAcv2ANuV
0
0
2
.@Schumacher_lab was bestowed the 2024 ESMO Award for Immuno-Oncology. He will deliver his award lecture on Wednesday, 11 December 2024 at the opening session of #ESMOImmuno24. ๐ https://t.co/Zj6zXD33Gt
0
6
18
#ESMOImmuno24: Real-world evidence has a place in #CancerImmunotherapy.โฏHowever, some challenges still limit its implementation in #ClinicalPractice. #ESMODailyReporter #ESMO-GROW @DoniaMarco ๐ https://t.co/OMpGFaycJ6
0
1
4
Welcome to Geneva ๐จ๐ญ for the much awaited #ESMOImmuno24! ๐ก Presenting your work at #ESMOImmuno24? Looking for a home for your research work? Consider submitting to @esmo_iotech: ๐ https://t.co/aNaYyBsNzM
0
1
5
๐ข Check out this original article by Konรฏg & colleagues @UniBasel_en @UniSpitalBasel ๐จ๐ญ. ๐ BaseTIL trial: A single-center investigator-initiated phase I study of TILs + nivolumab in patients with advanced melanoma. Available #OpenAccess ๐ https://t.co/pW84TNUHgj
esmoiotech.org
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is a personalized immunotherapy. The efficacy of TIL-ACT has been demonstrated prospectively in patients with advanced melanoma...
0
1
4
๐ข Check out this special case report by Monberg, Svane & colleagues @CCITdk @helsinkiuni @Rigshospitalet ๐ฉ๐ฐ๐ซ๐ฎ. ๐Combined treatment with TILs + oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. Available #OpenAccess ๐ https://t.co/11jzDB280O
esmoiotech.org
Despite significant advancements in the treatment of malignant melanoma, metastatic mucosal melanoma remains a therapeutic challenge due to its complex pathogenesis, distinct pathological character...
0
2
3
๐ข Check out this latest original article by @TGruijl & team @amsterdamumc. ๐งซAn organotypic human melanoma-in-skin model as an inย vitro tool for testing Vฮณ9Vฮด2-T cell-based immunotherapy. Available #OpenAccess ๐ https://t.co/m4wlsUwtWv
esmoiotech.org
Despite considerable advancements in cancer immunotherapy, advanced melanoma still presents a substantial clinical challenge. In an effort to explore treatment options, we examined the immunotherap...
0
0
0
๐ข Check out this latest original article by Yeghaian, @S_Trebeschi + colleagues ๐ณ๐ฑ๐จ๐ญ๐ฉ๐ฐ. ๐ฌ Integrated noninvasive dx for prediction of survival in immunotherapy: Longitudinal CT, blood tests & clinical parameters โถ๏ธ AI models. Available #OpenAccess ๐ https://t.co/VhAtEjahZp
esmoiotech.org
Integrating complementary diagnostic data sources promises enhanced robustness in the predictive performance of artificial intelligence (AI) models, a crucial requirement for future clinical valida...
0
0
0
๐ข Hear first hand from our Editor-in-Chief Prof @HaanenJohn about ESMO IOTECH - @myESMOโs peer-reviewed open-access specialised journal dedicated to publishing advances in immuno-oncology and technology ๐
0
3
6
๐ก Presenting your work at #ESMO24 in Barcelona ๐ช๐ธ? Looking for a home for your research work? Consider submitting to @esmo_iotech ๐ ๐ https://t.co/aNaYyBsfKe
0
3
5
#ESMO24: Do not miss the latest #CancerResearch brought to you by the #ESMOAmbassadors & become part of the conversation. ๐ https://t.co/aauzyigXbr
5
23
101
๐ข Check out this latest original article by van Duin & colleagues - a multicentre study ๐ณ๐ฑ. ๐ฌ Investigating association between TIL abundance in pre-tx primary/metastasis & development of severe irAEs in advanced melanoma. Available #OpenAccess ๐ https://t.co/vY8XFXzlA1
esmoiotech.org
The predictive value of tumor-infiltrating lymphocytes (TILs) in immune-related adverse event (irAE) development remains unknown, although an association between tumor immunogenicity and irAEs has...
0
1
1
๐ Latest REVIEW by Olivera & @DrIgMelero + colleagues on 'Regional and intratumoral adoptive T-cell therapy'. Available #OpenAccess ๐ https://t.co/fkN850gib1
0
2
4
Congratulations to our ESMO IOTECH's Editor-in-Chief @HaanenJohn for the 2024 ESMO Lifetime Achievement Award ๐
. Well-deserved distinction, and we are all so delighted! #ESMO24 @myESMO
#ESMO24: ESMO has announced the recipients of the 2024 ESMO Society Awards in recognition of their work in strengthening the oncology field and supporting fellow oncologists in their professional careers. ๐ https://t.co/llnv5PS2as
0
0
4
๐ There's still time to submit your work to this ESMO IOTECH Special Issue on 'Developments in Cell Therapy', with guest editors: @alena_grosvidal & @sklobuch. For further details, please check out:
๐จ SPECIAL ISSUE: Developments in Cell Therapy ๐จ โฐ Submit an original article/review by 1 July 2024 ๐ 2022 CiteScore: 5.5 ๐ Indexed on PMC & PubMed @NLM_NIH: 'Immunooncol Technol' Further details: https://t.co/LmeCbGYE6B Guest editors: @alena_grosvidal & @sklobuch
0
1
3
๐ข Check out this latest original article by @CostaSvedman & colleagues @KarolinskaUnsju
@KarolinskaInst. ๐ฅ Effect of glucocorticoids for the management of irAEs on outcome in IO-treated melanoma patients. Available #OpenAccess๐ https://t.co/8iJ6kwgfTd
esmoiotech.org
Immune-related adverse events (IRAEs) during therapy with immune checkpoint inhibitors (ICIs) are common, and their management sometimes requires glucocorticoids (GCs). Predictors for development of...
0
0
1
๐ Presenting your work at #ASCO24 in Chicago ๐บ๐ธ? Looking for a home for your research work? Consider submitting to @esmo_iotech ๐ https://t.co/aNaYyBsNzM
0
2
2
IOTECH aspires to provide a forum for today's leaders in the field of #ImmunoOncology. We welcome: โก๏ธpre-clinical/clinical studies โก๏ธsolid/haematological cancers โก๏ธtechnological advances that decipher & improve clinical outcomes Get in touch today!
0
8
8